SB-239065

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameSB-239065
Drug Alias NameSB-239065
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP38 α mitogen-activated protein kinase inhibitors
TargetsP38 α mitogen-activated protein kinase
Therapy Area/IndicationsInflammationArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSmithkline Beecham Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcSmithkline Beecham Plc
Active IndicationsN/A
Inactive IndicationsInflammationArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A